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Abstract. The antitumor properties of bacteria have been 
demonstrated over the past decades. However, the efficacy is 
limited and unclear. Furthermore, systemic infection remains 
a serious concern in bacteria treatment. In this study, the effect 
of YB1, a rationally designed ‘obligate’ anaerobic Salmonella 
typhimurium strain, on liver tumor growth and metastasis in 
a nude mouse orthotopic liver tumor model was investigated. 
The orthotopic liver tumor model was established in nude mice 
using the hepatocellular carcinoma cell line MHCC‑97L. Two 
weeks after orthotopic liver tumor implantation, YB1, SL7207 
and saline were respectively administered through the tail 
vein of the mice. Longitudinal monitoring of tumor growth 
and metastasis was performed using Xenogen IVIS, and direct 
measurements of tumor volume were taken 3 weeks after 
treatment. In vitro, MHCC‑97L and PLC cells were incubated 
with YB1 or SL7207 under anaerobic conditions. YB1 was 
observed to invade tumor cells and induce tumor cell apop-
tosis and death. The results revealed that all mice in the YB1 
group were alive 3 weeks after YB1 injection while all mice 
in the SL7207 group died within 11 days of the SL7207 injec-
tion. The body weight decreased by ~9% on day 1 after YB1 
injection and but subsequently recovered. Liver tumor growth 
and metastases were significantly inhibited following YB1 
treatment. By contrast to the control group, a large number of 
Gr1‑positive cells were detected on days 1 to 21 following YB1 
treatment. Furthermore, YB1 also effectively invaded tumor 
cells and induced tumor cell apoptosis and death. In conclu-
sion, YB1 suppressed liver tumor growth and metastasis in a 
nude mice liver tumor model. The potential mechanism may 
be through enhancing innate immune response and inducing 
tumor cell apoptosis and cell death.
Introduction
Hepatocellular carcinoma (HCC) is one of the most malignant 
tumors worldwide (1). Surgical therapies including hepatec-
tomy and liver transplantation are first‑line treatments for 
HCC patients, but the unlikelihood of early diagnosis and the 
high incidence of tumor recurrence and metastasis following 
surgery remain major obstacles (2,3). Non‑surgical treatments 
including radiofrequency ablation, alcohol injection and trans-
catheter arterial chemoembolization have made great advances 
in recent years. However, they have substantial limitations, 
including toxicity, insufficient tissue penetration and poor 
tumor targeting, which together often result in incomplete 
destruction of the tumors (4-6). Therefore, the development 
of novel adjuvant therapies for the suppression of liver cancer 
growth and metastasis is essential.
Researchers are now turning to bacterial treatments and 
consider this a promising new strategy in cancer therapy. 
Certain bacterial species including Salmonella, Clostridia 
and Bifidobacteria have been observed to preferentially 
replicate and accumulate in tumors (7‑11). Through observa-
tions and research over the past century, bacteria has been 
noted to affect the tumor in the following ways (12,13): i) as 
a tumoricidal agent; ii) as a vector for gene therapy; iii) as 
toxins for cancer treatment; iv) as bacterial spores; and v) as an 
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immunotherapeutic agent. However, major problems with using 
bacteria as anti‑cancer agents include the systemic infection of 
bacteria (7,14) and the inability to completely eradicate cancer 
cells. Wild‑type bacteria including Salmonella may induce 
severe infection, which may result in septic shock and high 
lethality (7). Therefore, researchers use autotrophic mutations 
to attenuate the virulence of Salmonella in diverse ways (15).
Previously, we engineered YB1, which was derived from 
the attenuated Salmonella strain SL7207 (16‑21). Although 
SL7207 has aroA and other pathogenic gene mutations, it is 
lethal for nude mice if administrated intravenously. In YB1, 
the essential gene asd was engineered to be controlled by the 
hypoxic promoter Pept and the antisense aerobic promoter 
SodA. The asd gene is a key enzyme in the synthesis of diami-
nopimelic acid (DAP), which is an essential component for the 
gram‑negative bacteria cell wall. A deficiency of asd expres-
sion or shortage of extrinsic DAP supply in the environment 
leads to bacterial lysis in a short period of time. Therefore, 
without additional DAP, YB1 only survives under hypoxic 
conditions (<0.5% oxygen) (20). However, the normal functions 
of YB1 are not affected. In a nude mouse breast tumor model, 
YB1 was rapidly eliminated from normal organs due to their 
normoxia conditions. However, in tumors, YB1 accumulated 
inside the hypoxic region and caused tumor regression (20).
In this study, we explored the potential anti‑cancer effect 
of YB1 on HCC using an orthotopic liver tumor animal model 
with distant metastatic potential. We observed that liver tumor 
growth was significantly inhibited following YB1 treatment. 
Furthermore, YB1 also significantly decreased the incidence 
of lung metastasis. These results indicate that YB1 has a great 
potential for liver cancer therapy and it provides a new model 
to study the mechanisms underlying the high efficacy of bacte-
rial suppression of liver cancer growth and metastasis.
Materials and methods
Orthotopic nude mice liver tumor model. The orthotopic liver 
tumor model was established in nude mice (male, 4-6 weeks 
old, 18‑24 g) obtained from the Lab Animal Unit of the 
University of Hong Kong (22). MHCC‑97L cells (6x105; Liver 
Cancer Institute, Fudan University, China) in 0.1 ml culture 
medium were injected subcutaneously into the right flank of 
the nude mice. Once the subcutaneous tumors reached 0.8 to 
1 cm in diameter, they were removed and cut into cubes 1 to 
2 mm3 in size, which were subsequently implanted into the left 
liver lobes of another group of nude mice. Mice were housed 
at room temperature (20‑25˚C) in a standard animal labora-
tory with free activity and access to water and food. The mice 
were maintained under constant environmental conditions 
with a 12‑h light‑dark cycle. All operations were performed in 
clean conditions. The present study was licensed according to 
Animal Ordinance Chapter 340 by the Department of Health, 
Hong Kong Special Administrative Region (ref. 13‑501 in 
DH/HA&P/8/2/3 Pt. 52).
Treatment regimen, imaging analysis and sample collection. 
Two weeks after tumor implantation, a single dose of 
SL7207 (5x107 CFU; lab stock; Stanford University School of 
Medicine, Stanford, CA, USA), YB1 (5x107 CFU; modified 
from SL7207) (20) or saline (control group; Thai Otsuka. 
Pharmaceutical Co., Ltd., Bangkok, Thailand) was injected 
via the tail vein. Five mice each from the SL7207 and YB1 
groups were used to observe the effect of bacteria on mouse 
survival. The control group mice (n=9) and the remaining nude 
mice from the YB1 group (n=14) were used to monitor liver 
tumor growth and metastasis using a Xenogen in vivo imaging 
system (PerkinElmer, Inc., Waltham, MA, USA) through the 
detection of luminance signals from tumor cells. The mice 
were sacrificed 3 weeks after the YB1 or saline injection. The 
tumors, livers and lungs were sampled for further research.
Hematoxylin and eosin (H&E) and immunohistochemical 
(IHC) staining. The histological changes were assessed by 
H&E staining (Vector Laboratories, Inc., Burlingame, CA, 
USA), and the infiltration of neutrophils was assessed by 
IHC. The tissue samples were fixed in 10% formalin and 
embedded in paraffin (Sigma‑Aldrich, St. Louis, MO, USA). 
Paraffin sections were dewaxed with xylene (Merck Milli-
pore, Darmstadt, Germany), rinsed in graded alcohol (Merck 
Millipore) and rehydrated in water, and subsequently were 
stained with H&E for histological examination. The distribu-
tion of YB1 in liver tissue was detected by IHC staining. The 
initial step was the same as H&E staining, but the paraffin 
sections then underwent antigen retrieval with citrate buffer 
(pH 6.0; Abcam, Cambridge, UK). Subsequently, the sections 
were blocked using 10% fetal bovine serum (Life Technolo-
gies Ltd.; Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
for 30 min, and rat anti‑mouse monoclonal primary antibody 
(dilution, 1:200; catalog no., 560454; BD Biosciences, Franklin 
Lakes, NJ, USA) was applied and incubated for 1 h. Following 
incubation, the sections underwent blocking with 3% peroxi-
dase (Dako, Glostrup, Denmark) for 30 min, and then goat 
anti‑rat polyclonal secondary antibody (dilution, 1:100; catalog 
no., 559286; BD Biosciences) was applied and incubated for 
30 min. The details of the H&E and IHC staining processes 
are described in a previous study by the same group (22).
Cell lines. Human HCC cell lines MHCC‑97L and PLC (Japa-
nese Cancer Research Bank; National Institutes of Biomedical 
Innovation, Health and Nutrition, Osaka, Japan) were main-
tained in high‑glucose Dulbecco's modified Eagle's medium 
(Life Technologies Ltd.; Thermo Fisher Scientific, Inc.) supple-
mented with 10% heat‑inactivated fetal bovine serum (Life 
Technologies Ltd.; Thermo Fisher Scientific, Inc.), 100 mg/ml 
penicillin G and 50 µg/ml streptomycin (Life Technologies Ltd., 
Thermo Fisher Scientific, Inc.) at 37˚C in a humidified atmo-
sphere containing 5% CO2. MHCC‑97L cells were labeled via 
stable transfer of the luciferase gene in chromosomes. Briefly, 
cells were transfected with pGL3 vector (Promega Corporation, 
Madison, WI, USA), and positive clones were selected according 
to luciferase activity in the Xenogen IVIS 100 imaging system 
(PerkinElmer, Inc., Waltham, MA, USA).
Salmonella invasion assay. YB1‑incubated MHCC‑97L and 
PLC cells were prepared and co‑cultured at a ratio of 1,000:1 
for 2 h under anaerobic (O2<0.5%) or aerobic conditions. 
Extracellular bacteria were then removed by washing with 
phosphate‑buffered saline (USB Corporation; Affymetrix, 
Inc., Santa Clara, CA, USA) and the cells were further 
cultured with gentamycin medium (Life Technologies Ltd., 
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Thermo Fisher Scientific, Inc.) for 24 h. Cells were fixed 
in paraformaldehyde (4%) and stained with a rabbit poly-
clonal anti-Salmonella antibody (dilution, 1:500; catalog 
no., ab35156; Abcam) for 12 h at 4˚C. Goat anti‑rabbit 
polyclonal immunoglobulin G Alexa Fluor® 488‑conjugated 
(dilution, 1:100; catalog no., ab150077) and polyclonal 
horseradish peroxidase‑conjugated (dilution, 1:100; catalog 
no., ab6721) secondary antibodies (Abcam) were added 
and the cells were incubated for 1 h at room temperature. 
Then CytoPainter Phalloidin‑iFluor 488 Reagent (dilution, 
1:1,000; catalog no., ab176753; Abcam) was applied to 
indicate cell boundaries. CytoPainter Phalloidin‑iFluor 555 
Reagent (dilution, 1:1,000; catalog no., ab176756; Abcam) 
was also applied to demonstrate cell boundaries. The cells 
were observed under a confocal microscope (LSM 710; Carl 
Zeiss AG, Oberkochen, Germany).
Detection of cell apoptosis. Cancer cell apoptosis and death 
induced by YB1 under anaerobic conditions was detected 
using an Annexin V‑propidium iodide (PI) kit (BioVision, 
Inc., Milpitas, CA, USA) according to the manufacturer's 
protocol. As demonstrated using flow cytometry (FACSCal-
ibur; (BD Biosciences) Annexin V1/PI‑ cells were apoptotic 
and Annexin V1/PI1 cells were dead.
Statistics and data analyses. Continuous variables were 
expressed as the median with a range. The t‑test was used 
for statistical comparison. The χ2 test was used to compare 
the incidence of lung metastasis. P<0.05 was considered to 
indicate a statistically significant difference. Calculations 
were performed using the SPSS computer software version 16 
(SPSS, Inc., Chicago, IL, USA).
Results
Effect and distribution of YB1 on nude mice bearing ortho-
topic liver tumors. Orthotopic liver tumor‑bearing mice were 
treated with parental strain SL7207 or engineered strain YB1 
for 3 weeks. All mice in the SL7207 group died within 11 days 
of treatment. All of the mice were alive and healthy 3 weeks 
after YB1 injection (Fig. 1). To monitor the healthy condition 
of YB1 treated mice, the body weights were recorded after 
injection. The results revealed that the body weight decreased 
by ~9% on day 1 after YB1 injection and recovered afterwards 
(Fig. 1B). Notably, we observed that YB1 had low‑level distri-
bution in the tumors. This result is different from that observed 
in our previous study in a breast tumor model (20). On day 21 
after treatment, only low amounts of YB1 were identified in 
the shrunken tumor by paraffin section staining (Fig. 1C). In 
addition, YB1 was entirely eliminated from the kidney, lymph 
nodes and spleen 3 weeks subsequent to injection. YB1 was 
undetected in the blood throughout the experiment.
YB1 significantly suppresses liver tumor growth and 
metastasis. The effect of YB1 on liver tumor growth and 
metastasis was studied using an orthotopic liver tumor model 
in nude mice. Tumor‑bearing mice were grouped randomly, 
and there were no significant differences in the average size 
of liver tumors between the treatment and control group when 
the experiment started. Longitudinal monitoring of tumor 
growth and metastasis was achieved by Xenogen IVIS and 
the tumor final volume was measured at 3 weeks after treat-
ment. The results indicated that YB1 significantly reduced the 
size of the primary liver tumor from 1 week to 3 weeks after 
treatment (Fig. 2A‑B). After 3 weeks, the tumors in the control 
Figure 1. YB1 distribution and effect on nude mice with orthotopic liver tumors (A) Survival rate of nude mice following YB1 and SL7207 injection (n=5 per 
group). (B) Body weight changes in nude mice were detected on day 1, 3, 7, 14 and 21 following YB1 treatment (treatment, n=14; control, n=9). *P<0.05 compared 
with mice following YB1 treatment. (C) YB1 was detected on tumor nodules 3 weeks after YB1 treatment (magnification, x100; immunohistochemical staining).
  A   B
  C
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and YB1‑treated groups demonstrated significant differences 
(580.1 mm3 vs. 61.2 mm3; P=0.000; Table I). Lung metastasis 
was totally repressed by YB1 treatment (0 of 14), however, the 
control group still demonstrated a 55.6% (5 of 9; P=0.004) 
lung metastasis rate (Table I). These results were additionally 
confirmed by histological examination (Fig. 2C).
Table I. Comparison of tumor size and lung metastasis in mice with or without YB1 treatment.
Variable Control (n=9) Treatment (n=14) P‑value
Tumor volume (mm3)a 580.1±218.4 61.2±32.1 0.000
Lung metastasis  5/9 (55.6%) 0/14 (0.0%) 0.004
aTumor volume, mean ± standard deviation.
Figure 2. Comparison of liver tumor growth and metastasis with and without YB1 treatment in a nude mice orthotopic liver tumor model. (A) Tumor growth 
was monitored by Xenogen IVIS at various time points following YB1 treatment. (B) Liver tumor growth and lung metastasis were inhibited at 3 weeks YB1 
treatment. (C) Histological features of liver tumors and lung metastatic tumors 3 weeks after treatment (treatment, n=14; control, n=9). Hematoxylin and eosin 
staining; magnification, x100.
  A
  B
  C
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YB1 enhances neutrophil infiltration in liver tissue. During 
inflammation of bacterial treatment, circulating neutrophils 
are recruited to the site of inflammation, which releases a 
number of various cytokines and enhances the innate immune 
response (19). In order to investigate the mechanism of YB1 
suppression of tumor growth and metastasis, the present study 
compared the infiltration of neutrophils in the liver between 
the YB1 treatment and control group. In the control group, 
only a small number of Gr1‑positive cells were detected during 
the entire experiment (Fig. 3). Large amounts of Gr1‑positive 
cells were detected on day 1 to day 21 following YB1 treat-
ment (Fig. 3).
YB1 effectively invades tumor cells and induces tumor cell 
apoptosis and death. To test the interaction between YB1 and 
liver cancer, MHCC‑97L and PLC cell lines were incubated 
with YB1 or SL7207 in vitro under anaerobic conditions 
(oxygen level below 0.5%). Following the removal of extra-
cellular bacteria and further culturing, it was demonstrated 
that SL7207 and YB1 effectively invaded the liver cancer 
cells (Fig. 4A). The effect of SL7207 and YB1 on tumor cells 
was further investigated by measuring tumor cell apoptosis 
and death. The results of the present study revealed that an 
increasing number of dying and apoptotic MHCC‑97L cells 
were detected following co‑culture with SL7207 or YB1, 
relative to the control. The YB1 and SL7207 groups exhibited 
significant damage to cancer cells under hypoxic conditions 
(Fig. 4B). Similar results were observed in the PLC cell line 
(Fig. 4B).
Discussion
In the present study, the significant effects of YB1 on the 
inhibition of HCC growth and metastasis were observed in an 
orthotopic liver tumor model with distant metastatic potential. 
With the application of Xenogen IVIS, a notable suppression 
of liver tumor growth by YB1 treatment was demonstrated 
longitudinally at different time points. In addition to the inhi-
bition of primary liver tumor growth, YB1 also significantly 
decreased the incidence of lung metastasis. In contrast with the 
SL7207 group, all mice in the YB1 group were alive 3 weeks 
after YB1 injection. Although body weights decreased for a 
short period, they were restored to their original states within 
days. The data suggested that YB1 has no severe adverse 
effects and hence may be a new option in the therapy of HCC 
patients.
Compared with our previous studies, YB1 treatment in 
the liver cancer model demonstrated better results, with the 
primary tumor being greatly repressed and lung metastasis 
totally eliminated. To explore the underlying mechanism, we 
investigated two potential directions. First, the innate immune 
response induced by YB1. A tumor has the ability to escape 
the immune system due to the development of tolerance. 
Numerous methods have been used in attempts to alert the 
immune system to the presence of tumors. In previous studies, 
immunotherapeutic strategies employ bacteria including 
Salmonella to enhance the antigenicity of tumor cells (23‑25). 
Studies by Avogadri et al and Al Ramadi et al revealed that 
attenuated S. typhimurium infects malignant cells and trig-
gers an anti‑cancer immune response (26,27). Furthermore, 
S. typhimurium plays a significant role in the induction of poly-
morphonuclear leukocyte migration through its Salmonella 
invasion protein A (SipA) (28). The present study confirmed 
that YB1 enhances innate immune response by increasing the 
infiltration of neutrophils. The results indicate that the suppres-
sion effect of YB1 on tumor growth and metastasis may be due 
to its ability to enhance the innate immune response.
Secondly, due to the ability of YB1 to penetrate deep inside 
the tumor and gain direct contact with cancer cells, we also 
further explore the direct effect of YB1 on HCC cells. In the 
present study, our results revealed that YB1 effectively invades 
HCC cells and induces tumor cell apoptosis and death. This 
is consistent with our previous results (20). A previous study 
reveals that S. typhimurium may activate specific apoptotic 
enzymes including caspase‑3 through S. typhimurium effector 
SipA (29). The activation of caspase‑3 in turn increases the 
infectivity of this pathogen by enhancing the secretion of effec-
tors (28,29). Furthermore, the activation of cleaved caspase‑3 
is linked to tumor cell apoptosis (30). Therefore, these data 
suggested that the suppressive effect of YB1 on tumor growth 
and metastasis might be attributed to the induction of apop-
tosis. However, the precise mechanism of YB1 on induced 
tumor cell apoptosis requires further investigation.
In conclusion, YB1 suppresses liver tumor growth and 
metastasis by inducing HCC cell apoptosis and enhancing the 
innate immune response, suggesting that it may be a promising 
candidate for potential adjuvant therapies for HCC patients.
Figure 3. YB1 enhances neutrophil infiltration in liver tissue. Gr1 expression 
was detected by immunohistochemical staining (treatment, n=14; control, 
n=9). Magnification, x100.
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Figure 4. YB1 invades tumor cells and induces tumor cell apoptosis and death. Liver cancer cell lines MHCC‑97L and PLC were incubated with YB1 or 
SL7207 under anaerobic conditions (oxygen level below 0.5%). (A) YB1 as well as SL7207 effectively invades tumor cells. (B) YB1 induces MHCC‑97L and 
PLC tumor cell apoptosis and death.
  A
  B
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